Targeted protein degradation with small molecules for cancer immunotherapy
Immunotherapy has transformed cancer treatment, marked by the approval of numerous antibody-based drugs. However, the limitations of antibodies in pharmacokinetics including long half-lives, limited oral bioavailability and immunogenicity, have prompted the pursuit of small molecule-based immunother...
Saved in:
| Main Authors: | Zichao Yang, Jianwei Xu, Xixiang Yang, Jianjun Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Asian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S181808762500042X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Indoleamine 2,3-dioxygenase 1 in cancer immunotherapy: from small-molecule inhibition to PROTAC-mediated degradation
by: Xiuyun Li, et al.
Published: (2025-08-01) -
GPC3-mediated lysosome-targeting chimeras (GLTACs) for targeted degradation of membrane proteins
by: Yuxin Fang, et al.
Published: (2025-04-01) -
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs
by: M. A. A. Mamun, et al.
Published: (2025-05-01) -
Towards the Rational Design of Monovalent Degraders: Lessons Learnt from Cyclin K Degraders
by: Katie L. Thomas, et al.
Published: (2025-03-01) -
Small molecule inhibitors targeting the cancers
by: Gui‐Hong Liu, et al.
Published: (2022-12-01)